PRognosis Evaluation using in-Depth immune phenotyping and metagenomic analysis In Colorectal cancer Therapy

ABSTRACT: Interventions: Group 1: Surgical patients undergoing surgery for colorectal cancer: immunophenotyping by PBMCs and metagenomic analyses from stool, mucosa, and saliva samples perioperatively and during oncologic follow-up. Group 2: oncologic patients with chemo- / immune therapy without recent surgery: Immunophenotyping by PBMCs and metagenomic analyses from stool, mucosa and saliva samples during therapy and oncological follow-up. Group 3: healthy controls: Immunophenotyping by PBMCs and metagenomic analyses from stool, mucosa, and saliva samples at the time of screening colonoscopy. Primary outcome(s): Difference in the differential abundance of the colonic mucosa of patients with CRC vs. healthy controls for evaluation as diagnostic biomarkers based on metagenomic analyzes (microbial pattern) Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: diagnostic

DISEASE(S): Malignant Neoplasm Of Rectum,Malignant Neoplasm Of Rectosigmoid Junction,Malignant Neoplasm Of Colon

PROVIDER: 2439680 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR